Araştırma Makalesi

Investigation of the potential antitumor activity of PLK1 inhibitor SBE13 in colon cancer cell line HT29

Cilt: 44 Sayı: 2 30 Haziran 2022
Cumhuriyet Tıp Dergisi Kapak
Cumhuriyet Tıp Dergisi
PDF İndir
EN

Investigation of the potential antitumor activity of PLK1 inhibitor SBE13 in colon cancer cell line HT29

Abstract

Background: High levels of Polo-like kinase 1 (PLK1), which are abnormally expressed in many tumor types, are known to contribute to tumorigenesis and poor prognosis. Therefore, specific targeting of PLK1 is an important strategy for cancer therapy. This study, it was aimed to investigate the cytotoxic effect of SBE13, one of the PLK1 inhibitors, against HT29 colon adenocarcinoma cells and its apoptotic potential.
Methods: The cytotoxic effect of SBE13 on HT29 was determined by XTT colorimetric assay. Flow cytometry was also used to determine apoptosis.
Results: SBE13 showed a dose-dependent cytotoxic effect in HT29 cells and its IC50 value was calculated as 11.79 µM for 48 h. Moreover, the Annexin V binding assay revealed that SBE13 treatment significantly increased apoptosis in HT29 cells.
Conclusion: Generally, SBE13 exerts a cytotoxic effect promoted by apoptosis in colon cancer cells HT29. Although the anticancer efficacy of SBE13 in colon cancer is promising, this potential effect should be reinforced by further studies.

Keywords

Kaynakça

  1. 1. Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019. CA: A Cancer Journal for Clinicians. 2019;69(5):363-385.
  2. 2. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians. 2021;71(3):209-249.
  3. 3. Combes G, Alharbi I, Braga LG, Elowe S. Playing polo during mitosis: PLK1 takes the lead. Oncogene. 2017;36(34):4819-4827.
  4. 4. Lowe SW, Lin AW. Apoptosis in cancer. Carcinogenesis. 2000;21(3):485-495.
  5. 5. Chopra P, Sethi G, Dastidar SG, Ray A. Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics. Expert opinion on investigational drugs. 2010;19(1):27-43.
  6. 6. Strebhardt K, Ullrich A. Targeting polo-like kinase 1 for cancer therapy. Nature Reviews Cancer. 2006;6(4):321-330.
  7. 7. Shi J, Ren Y, Ma J, et al. Novel CD44-targeting and pH/redox-dual-stimuli-responsive core–shell nanoparticles loading triptolide combats breast cancer growth and lung metastasis. Journal of Nanobiotechnology. 2021;19(1):188.
  8. 8. Degenhardt Y, Lampkin T. Targeting Polo-like kinase in cancer therapy. Clinical cancer research. 2010;16(2):384-389.

Ayrıntılar

Birincil Dil

İngilizce

Konular

Sağlık Kurumları Yönetimi

Bölüm

Araştırma Makalesi

Yazarlar

Yayımlanma Tarihi

30 Haziran 2022

Gönderilme Tarihi

21 Nisan 2022

Kabul Tarihi

27 Haziran 2022

Yayımlandığı Sayı

Yıl 2022 Cilt: 44 Sayı: 2

DOI

https://doi.org/10.7197/cmj.1107200

IZ

https://izlik.org/JA63LR67RP

Kaynak Göster

RIS / Bibtex
AMA
1.Gömeç M, Yulak F, Ergül M. Investigation of the potential antitumor activity of PLK1 inhibitor SBE13 in colon cancer cell line HT29. CMJ. 2022;44(2):218-222. doi:10.7197/cmj.1107200